Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

May 01, 2020 11:00am EDT

CohBar’s Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

Apr 30, 2020 9:00am EDT

CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020

Apr 14, 2020 8:30am EDT

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference

Mar 30, 2020 8:45am EDT

CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity

Mar 12, 2020 4:02pm EDT

CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update

Mar 12, 2020 8:30am EDT

CohBar to Hold Investor Meetings at the ROTH Virtual Conference

Mar 02, 2020 4:30pm EST

CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020

Jan 28, 2020 9:00am EST

CohBar to Present at the 2020 BIO CEO & Investor Conference

Jan 22, 2020 9:00am EST

CohBar Appoints Jordyn Tarazi as Director of Investor Relations

Jan 08, 2020 9:00am EST

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis